MedPath

Pilot/Pivotal Study of DBS+Rehab After Stroke

Not Applicable
Recruiting
Conditions
Upper Extremity Paresis
Stroke
Interventions
Other: Rehabilitation
Device: Deep Brain Stimulation
Registration Number
NCT05701280
Lead Sponsor
Enspire DBS Therapy, Inc.
Brief Summary

The RESTORE Stroke Study will evaluate the safety and effectiveness of DBS+Rehab for treating arm weakness and reduced function after a stroke.

Detailed Description

The RESTORE Stroke Study combines two phases of study under one protocol (pilot/pivotal). The first phase has a sample size of 40 subjects. The second phase has an estimated sample size of 162 subjects which may be adjusted based on analysis of the first phase.

Each subject will be implanted with the DBS system, undergo DBS program optimization, and be randomized to test treatment (Tt) or active-control treatment (Ct). After randomization, all subjects will participate in a five-month outpatient rehabilitation therapy program. After five months of blinded randomized testing, subjects assigned to active-control treatment (Ct) will cross over to receive test treatment (Tt) and participate in a second five-month therapy program.

Recruitment & Eligibility

Status
RECRUITING
Sex
All
Target Recruitment
202
Inclusion Criteria
  • Ischemic stroke, with an initial incident occurring between 12 months to 6 years before implant, resulting in residual upper extremity hemiparesis.

Key

Exclusion Criteria
  • Previous or subsequent cerebrovascular events resulting in residual upper extremity impairment
  • Brain lesions with significant involvement of the brainstem, cerebellum, or thalamus

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
RehabRehabilitationControl-DBS combined with motor rehabilitation
DBS+RehabDeep Brain StimulationActive-DBS combined with motor rehabilitation
Primary Outcome Measures
NameTimeMethod
Fugl-Meyer Assessment, Upper Extremity sub-scale (FMA-UE)Week-12 to Week-32

The change in FMA-UE is significantly greater for subjects who receive Test treatment (Tt) than Control treatment (Ct).

Secondary Outcome Measures
NameTimeMethod
Fugl-Meyer Assessment, Upper Extremity sub-scale (FMA-UE)Week-12 to Week-32

The change in FMA-UE for subjects who receive Test treatment (Tt) is significantly above a clinically important difference (CID)

Trial Locations

Locations (7)

Thomas Jefferson University

🇺🇸

Philadelphia, Pennsylvania, United States

Barrow Neurological Institute (BNI)

🇺🇸

Phoenix, Arizona, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

Cleveland Clinic

🇺🇸

Cleveland, Ohio, United States

Rhode Island Hospital

🇺🇸

Providence, Rhode Island, United States

Medical University of South Carolina (MUSC)

🇺🇸

Charleston, South Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath